Researchers report on ctDNA-based detection of residual disease prognostic for resected CRC

For patients with radically resected, stage II to IV colorectal cancer (CRC), circulating tumor (ct)DNA-based detection of molecular residual disease (MRD) in response to adjuvant chemotherapy (ACT) is prognostic of outcomes, according to a study presented at the American Society of Clinical Oncology annual Gastrointestinal Cancers Symposium, held from Jan. 18 to 20 in San Francisco.

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart